NIH CounterACT Program

“The CounterACT Program supports basic and translational research aimed at the identification of better therapeutic medical countermeasures against chemical threat agents, and facilitates their movement through the drug development and regulatory process in collaboration with other federal partner departments, agencies, and initiatives.”  (9/24/18 – See NIH CounterACT Program)

Other funded CounterACT Research Centers of Excellence include:

UMDNJ/Rutgers University CounterACT Research Center of Excellence 
Jeffrey D. Laskin, Ph.D.
RBHS-School of Public Health
U54AR055073

Development of Antidotes for Toxic Gases
Carl W. White, M.D.
University of Colorado, Denver
U54ES027698

Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication 
Pamela J. Lein, Ph.D.
University of California, Davis
U54NS079202

A Discovery and Development Pipeline for Cyanide Countermeasures
Calum A. MacRae, M.D., Ph.D.
Brigham and Women’s Hospital
U54NS079201